Carla Climent Vicente (@carlaclimentonc) 's Twitter Profile
Carla Climent Vicente

@carlaclimentonc

MD. Medical Oncologist. [email protected]

ID: 1569282191317782528

calendar_today12-09-2022 11:10:41

12 Tweet

36 Takipçi

89 Takip Edilen

Júlia Giner (@juliaginerj) 's Twitter Profile Photo
Júlia Giner
@juliaginerj

3 years ago

La Dra Carla Climent, R5 d’oncologia mèdica del Consorci Corporació Sanitària Parc Taulí al congrés europeu d’oncologia mèdica ESMO - Eur. Oncology #ESMO22 OncoTauli 👏🏻🫁🎯

La Dra Carla Climent, R5 d’oncologia mèdica del <a href="/parctauli/">Consorci Corporació Sanitària Parc Taulí</a> al congrés europeu d’oncologia mèdica <a href="/myESMO/">ESMO - Eur. Oncology</a> #ESMO22 <a href="/OncoTauli/">OncoTauli</a> 👏🏻🫁🎯
Laia Vilà (@_vila_l) 's Twitter Profile Photo
Laia Vilà
@_vila_l

3 years ago

KRAS all stages NSCLC by Carla Climent, from Consorci Corporació Sanitària Parc Taulí Poster presented #ESMO22 ESMO - Eur. Oncology Great job! #NSCLC #lungcancer

KRAS all stages NSCLC by Carla Climent, from <a href="/parctauli/">Consorci Corporació Sanitària Parc Taulí</a> Poster presented #ESMO22 <a href="/myESMO/">ESMO - Eur. Oncology</a> Great job! #NSCLC #lungcancer
Carla Climent Vicente (@carlaclimentonc) 's Twitter Profile Photo
Carla Climent Vicente
@carlaclimentonc

3 years ago

Feliz de haber presentado nuestro trabajo “Molecular characterization of KRAS NSCLC all stages: a single-center cohort” en ESMO 2022 #ESMO22 ⁦ESMO - Eur. Oncology⁩ #KRAS #NSCLC

Feliz de haber presentado nuestro trabajo “Molecular characterization of KRAS NSCLC all stages: a single-center cohort” en ESMO 2022 #ESMO22 ⁦<a href="/myESMO/">ESMO - Eur. Oncology</a>⁩ #KRAS #NSCLC
Dr. Antonio Calles 🫁🚭 (@tony_calles) 's Twitter Profile Photo
Dr. Antonio Calles 🫁🚭
@tony_calles

3 years ago

Dra. Carla Climent, de la Corporació Sanitària Parc Tauli. Características clínicas-patológicas de las mutaciones KRAS en cáncer de pulmón. N=62 #SEOM22 SEOM #LCSM

Dra. Carla Climent, de la Corporació Sanitària Parc Tauli. Características clínicas-patológicas de las mutaciones KRAS en cáncer de pulmón. N=62 #SEOM22 <a href="/_SEOM/">SEOM</a> #LCSM
Carla Climent Vicente (@carlaclimentonc) 's Twitter Profile Photo
Carla Climent Vicente
@carlaclimentonc

3 years ago

Hoy hemos presentado nuestro trabajo como sesión oral de pulmón en SEOM 2022 : NSCLC mutación KRAS, caracterización en todos los estadios. SEOM #SEOM22

Hoy hemos presentado nuestro trabajo como sesión oral de pulmón en SEOM 2022 : NSCLC mutación KRAS, caracterización en todos los estadios. <a href="/_SEOM/">SEOM</a> #SEOM22
Tom Powles (@tompowles1) 's Twitter Profile Photo
Tom Powles
@tompowles1

3 years ago

Hot Topics in GU in Canary Islands. The clear benefits for VEGF/PD1 combs vs sunitinib in good risk mRCC is less clear looking maturing OS data. Also, ipi/nivo, which was initially worse than VEGF TKI now looks the same. Daniel Castellano Uromigos Brian Rini, MD Guillermo de Velasco

Hot Topics in GU in Canary Islands. The clear benefits for VEGF/PD1 combs vs sunitinib in good risk mRCC is less clear looking maturing OS data. Also, ipi/nivo, which was initially worse than VEGF TKI now looks the same. <a href="/cdanicas/">Daniel Castellano</a> <a href="/Uromigos/">Uromigos</a> <a href="/brian_rini/">Brian Rini, MD</a> <a href="/g_develasco/">Guillermo de Velasco</a>
Carla Climent Vicente (@carlaclimentonc) 's Twitter Profile Photo
Carla Climent Vicente
@carlaclimentonc

3 years ago

After diligent efforts our work on “The role of immunotherapy in non-clear cell renal cell carcinoma” is finally published Enrique Gallardo frontiersin.org/articles/10.33…

Frontiers - Oncology (@frontoncology) 's Twitter Profile Photo
Frontiers - Oncology
@frontoncology

3 years ago

New research: The role of immunotherapy in non-clear cell renal cell carcinoma: The category of non-clear cell renal cell carcinoma (nccRCC) includes several clinically, histologically, and molecularly diverse entities. Traditionally, they… frontiersin.org/articles/10.33… #oncology

Dr Imran Sheikh 🩺 (@drimransheikh) 's Twitter Profile Photo
Dr Imran Sheikh 🩺
@drimransheikh

3 years ago

The role of immunotherapy in non-clear cell renal cell carcinoma frontiersin.org/articles/10.33…

The role of immunotherapy in non-clear cell renal cell carcinoma frontiersin.org/articles/10.33…
Dr. Iván R. González (@dr_ivanoncologo) 's Twitter Profile Photo
Dr. Iván R. González
@dr_ivanoncologo

3 years ago

Interesting article the ICI's targeting programmed death ligand 1 and protein 4 associated with cytotoxic T lymphocytes (CTLA-4), has increased survival in several malignancies, including carcinoma of unclear renal cells. frontiersin.org/articles/10.33…

Interesting article the ICI's targeting programmed death ligand 1 and protein 4 associated with cytotoxic T lymphocytes (CTLA-4), has increased survival in several malignancies, including carcinoma of unclear renal cells. frontiersin.org/articles/10.33…
Laia Vilà (@_vila_l) 's Twitter Profile Photo
Laia Vilà
@_vila_l

3 years ago

OFERTA LABORAL ⬇️⬇️ 🫁 Especialista en Oncología médica en el Hospital Parc Taulí de Sabadell seom.org/otros-servicio… vía SEOM